Encrypted login | home

Program Information

Towards a Novel Treatment Planning Pipeline Delivering Pareto-Optimal Plans While Enabling Inter- and Intrafraction Plan Adaptation

no image available
C Kontaxis

C Kontaxis1*, S Breedveld2 , G Bol1 , A Sharfo2 , B Heijmen2 , J Lagendijk1 , B Raaymakers1 , (1) University Medical Center Utrecht, Utrecht, The Netherlands, (2) Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands


SU-F-J-105 (Sunday, July 31, 2016) 3:00 PM - 6:00 PM Room: Exhibit Hall

To develop a new IMRT treatment planning methodology suitable for the new generation of MR-linear accelerator machines. The pipeline is able to deliver Pareto-optimal plans and can be utilized for conventional treatments as well as for inter- and intrafraction plan adaptation based on real-time MR-data.

A Pareto-optimal plan is generated using the automated multicriterial optimization approach Erasmus-iCycle. The resulting dose distribution is used as input to the second part of the pipeline, an iterative process which generates deliverable segments that target the latest anatomical state and gradually converges to the prescribed dose. This process continues until a certain percentage of the dose has been delivered. Under a conventional treatment, a Segment Weight Optimization (SWO) is then performed to ensure convergence to the prescribed dose. In the case of inter- and intrafraction adaptation, post-processing steps like SWO cannot be employed due to the changing anatomy. This is instead addressed by transferring the missing/excess dose to the input of the subsequent fraction. In this work, the resulting plans were delivered on a Delta4 phantom as a final Quality Assurance test.

A conventional static SWO IMRT plan was generated for two prostate cases. The sequencer faithfully reproduced the input dose for all volumes of interest. For the two cases the mean relative dose difference of the PTV between the ideal input and sequenced dose was 0.1% and -0.02% respectively. Both plans were delivered on a Delta4 phantom and passed the clinical Quality Assurance procedures by achieving 100% pass rate at a 3%/3mm gamma analysis.

We have developed a new sequencing methodology capable of online plan adaptation. In this work, we extended the pipeline to support Pareto-optimal input and clinically validated that it can accurately achieve these ideal distributions, while its flexible design enables inter- and intrafraction plan adaptation.

Funding Support, Disclosures, and Conflict of Interest: This research is financially supported by Elekta AB, Stockholm, Sweden.

Contact Email: